| Autor: |
Mansour RO; Mansoura Manchester Medical Program, Faculty of Medicine, Mansoura University, Mansoura, Egypt., El-Ashwah S; Clinical Hematology Department, Oncology Center, Faculty of Medicine, Mansoura University, Mansoura, Egypt., Denewer M; Clinical Hematology Department, Oncology Center, Faculty of Medicine, Mansoura University, Mansoura, Egypt. |
| Jazyk: |
angličtina |
| Zdroj: |
Blood research [Blood Res] 2023 Mar 31; Vol. 58 (1), pp. 13-19. Date of Electronic Publication: 2023 Feb 08. |
| DOI: |
10.5045/br.2023.2022144 |
| Abstrakt: |
This study aimed to delineate the possible impact of COVID-19 on acute myeloid leukemia (AML) patients in terms of diagnosis, chemotherapy, bone marrow transplant, and vaccination response. Allogeneic stem cell transplantation is markedly affected by the COVID-19 pandemic, as both donors and recipients must be healthy for transplantation to be feasible and successful. Delays in the identification of well-matched donors have been predicted, and represent a special challenge. Therefore, future donors should be tested for COVID-19. The outcome of delayed transplantation is vague and masked by variations in stem cell source along with disease subtype. However, if transplant delay results in recurrence of minimal residual disease, a negative impact on survival is anticipated. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
